- Home
- / Travere Therapeutics
Travere Therapeutics
Stock Price
$18.4
2024-10-29
Market Capitalization
$1.4 B
2024-10-29
Revenue
$490.7 M
FY, 2025
Travere Therapeutics Summary
Company Summary
- Overview
- Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam, and Thiola.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- San Diego, CA, US | view all locations
- Website
- https://travere.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Eric Dube, President & Chief Executive Officer
Peter Heerma, Chief Commercial Officer
Tim Coughlin, Director
LocationsView all
2 locations detected
San Diego, CA HQ
United States
3721 Valley Centre Dr #200san
Dublin, D
Ireland
2nd Floor, Palmerston House, Fenian St
Travere Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $127.2M
- Gross profit (Q1, 2026)
- $125.2M
- Net income (Q1, 2026)
- ($37.1M)
- Cash (Q1, 2026)
- $78.4M
- EBIT (Q1, 2026)
- ($36.9M)
- Enterprise value
- $1.3B